High-Tech Gründerfonds (HTGF)

Industrifonden is a venture capital fund backing transformative ventures with the power to change the way we live for the better. We look for unique, scalable innovations that have a meaningful impact on our society. Industrifonden was founded by the Swedish government in 1979 as an independent foundation to provide Swedish industry with an innovation growth engine. For more than forty years, we have partnered with high-tech ventures in deep tech, life science, and transformative business. Today, we are an independent venture capital fund continuing our legacy by partnering with innovators and entrepreneurs to bring Nordic breakthrough innovations to the world. We partner with passionate founders that can turn their ideas into reality and change the industry – or create a totally new one. We primarily invest in Swedish innovations, as well as the Life Science and Deep Tech industries across the Nordics. At Industrifonden, we focus less on short-term wins and more on successful long-term investments that will create lasting value and benefits to our society. We’re in it for the long run, because experience has taught us that developing fundamental innovations takes time. Our areas of expertiseDeep Tech: We invest in advanced technology that addresses important societal issues. We have a special interest in advanced materials, industry 4.0, energy, advanced computing, AI, and synthetic biology. Life science: We invest in the commercialization of products and services, grounded in solid science, which address an unmet medical need. We have expertise in biotech, medtech and healthtech. Transformative tech: We invest in transformative tech and business models to create the industry of tomorrow. We mostly stay within the B2B space but invest in a broad range of industry verticals. Seed to A-round funding We invest in early-stage companies, from seed to A-round funding, and sometimes earlier. Our first ticket is often 10-50 million SEK, with the capacity to invest considerably more during the lifecycle. Smaller tickets are also considered in an earlier stage for exceptional technologies. In it for the long run Our fund has an evergreen structure allowing us to focus less on short-term wins and focus more on investments that will create long-term value. What we look for Unique, scalable innovations that have a meaningful impact on our society. Passionate founders that can turn their ideas into reality. Ideas with the potential to change a whole industry – or create a new one. If this sounds like you, share your pitch deck with us! Your pitch deck should include a clear problem statement, unique solution, target market, business model, team, financial projections, roadmap, cap-table and a clear ask. We value creativity, innovation, and collaboration.

Willkommen beim Life Science Valley Wachstumsfonds, einem neuen Frühphasen-Risikokapitalfonds mit Sitz in Göttingen, Niedersachsen. Unser Ziel ist es, Innovation im regionalen Ökosystem der Biowissenschaften zu fördern, indem wir vielversprechenden Start-ups und aufstrebenden Unternehmen Finanzmittel und Ressourcen zur Verfügung stellen. Unser Fonds sucht aktiv nach Investitionsmöglichkeiten in einer Vielzahl von Biowissenschaftssektoren, darunter Biotechnologie, Medizintechnik und digitale Gesundheit. Wenn Sie daran interessiert sind, mehr über unseren Fonds zu erfahren oder Ihre Idee vorzustellen, nehmen Sie Kontakt mit uns auf. Wir freuen uns auf die Zusammenarbeit mit Ihnen, um die Zukunft der Life-Science-Innovation in Niedersachsen und darüber hinaus zu gestalten. Investmentfokus Der frühphasige Fonds für Life Science Technologieausgründungen in Niedersachsen Der Fonds in Niedersachsen um die lokalen kommerziellen und unternehmerischen Potenziale der exzellenten Life Science Forschung und Technologien zu heben. Unterstützung von frühphasigen, nieder-sächsischen Unternehmen in den Bereichen BioTech, MedTech, Digital Health und Agriscience. Förderung erfolgreicher Unternehmensgründungen in technologischen Wachstumsfeldern. Inhaltlicher Fokus auf Life Sciences und klare Investmentkriterien als Basis für Erfolg Niedersächsische Life Science Unternehmen, u.a.: Biotechnologische Wirkstoffentwicklung und Verfahren Neuartige Schlüsseltechnologien in der Bio-Medizin, Medizintechnik, Diagnostik und Molekularbiologie (Digital) Life Science Tools für Entwicklung und Produktion von medizinischen Wirkstoffen sowie pflanzlichen Traits (Digitale) Tools zur Verbesserung von klinischen Prozessen Extended Life Sciences, z. B. Agri-Life Sciences, Human Mobility Solutions, etc. Markt: Nachweisbarer klinischer Bedarf „unmet medical/clincial need“ bzw. Marktbedarf Team: Interdisplizinäres und unternehmerisches Team mit hoher wissenschaftlicher, technologischer und wirtschaftlicher Kompetenz Synergiepotenziale: Hohes Potential für Zusammenarbeit und Kollaboration zwischen dem Start-up, relevanten Partnern im Ökosystem und unserem Fonds-Team Umsetzbarkeit: Klar definierter Entwicklungspfad bis zur Marktreife Value Proposition: Nachhaltige Alleinstellung gegenüber potenziellen Wettbewerbern z.B. über gesicherte IP Finanzierbarkeit: Realistische Finanzierbarkeit des weiteren Entwicklungsverlaufs

Bio&Tech Smart Capital is the alliance of researchers and entrepreneurs with Venture Capital management professionals to transfer scientific knowledge to society, with the aim of transforming spin off projects and startups that emerge from universities into solid and profitable companies. innovation laboratories and institutions. Investment criteria Bio&Tech Smart Capital focuses its activity focus on: Digital technologies applied to life sciences (focus on automation and data science). Biotechnology. Diagnostics and medical devices. Sustainability. Selected for the combination of: social impact, potential profitability and the experience and knowledge of the sector of the team. Diversification : no sector will represent more than 50% of the invested capital.

CDL has designed a new approach to enterprising research and innovation, nurturing an entrepreneurial mindset through expert opinion, funding opportunities, research analysis, and business development support. CDL’s objective-setting process enhances the performance of technical founders who learn from the insights of experienced entrepreneurs, increasing their probability of success. The Program involves:Mentorship from select entrepreneurs and angel investors: the Fellows and Associates Intensive full-day sessions with the CDL Mentors take place every eight weeks with the purpose of assessing progress and setting new short-term objectives. Fellows and Associates provide professional judgment (entrepreneurial knowledge) to help guide CDL Ventures and prioritize actions. The program is designed for early-stage, science-based technology companies, though we consider all applicants based on their potential to scale and the viability of their product. CDL’s objective-setting process enhances the performance of technical founders who learn from the insights of experienced entrepreneurs, increasing their probability of success. Opportunities to raise capital CDL Mentors are made up of a carefully selected group of exited entrepreneurs, angel investors, and partners from leading venture capital firms. These participants often invest in ventures that demonstrate a track record of achieving their objectives. Advice on technology roadmaps from CDL’s Chief Scientists World-renowned experts from leading academic institutions provide technical feedback to founders and advise the Fellows and Associates on objectives related to technology validation. Business development support from top students Business school students work to support ventures including developing financial models, evaluating potential markets, and fine-tuning strategies for scaling. Twelve locations globally CDL operates five sites in Canada, three in the United States and four in Europe. Launched in 2012 at the Rotman School of Management at University of Toronto, the program has now expanded with locations in Oxford (Saïd Business School, University of Oxford), Paris (HEC Paris), Atlanta (Scheller College of Business, Georgia Institute of Technology), Madison (Wisconsin School of Business, University of Wisconsin-Madison), Seattle (University of Washington, Foster School of Business), Berlin (European School of Management and Technology), Tartu (Delta Management School, University of Tartu), Vancouver (Sauder School of Business, University of British Columbia), Montreal (HEC Montréal), Calgary (Haskayne School of Business, University of Calgary), and Halifax (Rowe School of Business, Dalhousie University).

Lingotto’s Innovation Fund is a new $600mm+ AUM crossover (public & private) fund focused on making concentrated and long-term investments in companies operating at the cutting edge of technological and business-model innovation. Core to our investment thesis is the fact that market returns are dominated by extreme structural winners – we seek to identify decades-long secular trends and the management teams best positioned to capitalize on them in the early years. The senior team has a notable history of private investments including: OpenAI, SpaceX, Alibaba, Coupang, Stripe, Databricks, Spotify, Airbnb, Tempus, Recursion, Ginkgo Bioworks, Palantir, Epic Games, Joby Aviation, Indigo, Aira, Humane, H2 Green Steel. The Innovation Fund is co-managed by James Anderson (CIO & Managing Partner) and Morgan Samet (Co-Head & Managing Partner). James has over 40 years of investment experience – most recently as a Partner at Baillie Gifford, where he managed over £100bn in AUM throughout his tenure. As head of the firm’s flagship fund, the Scottish Mortgage Investment Trust, he delivered a +1,555% return vs. +354% for the FTSE all-world benchmark (between April 2000 and March 2022). He was instrumental in the firm’s move into private investing starting with Alibaba in 2012. Morgan has over 19 years of experience in private and public market investing. She has previously worked at Belfer Management, Pzena Investment Management, Thomas H. Lee Partners, and Goldman Sachs. She received her MBA from Harvard Business School. The Innovation Fund is a part of Lingotto, a $4.5bn+ investment management company supported with permanent capital from Exor and additional external LPs. Exor is one of Europe’s largest publicly traded holding companies. Its assets include companies like Stellantis (Fiat, Chrysler, Citroen), Ferrari, Philips, Juventus Football Club, the Economist and Christian Louboutin. Exor’s CEO is John Elkann (Chairman of Ferrari); its Chairman is Nitin Nohria (Executive Chairman of Thrive Capital and former Dean of Harvard Business School). Lingotto’s Chairman is George Osborne, former UK chancellor.